NCT04478708View on ClinicalTrials.gov

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

November 18, 2022

Study Completion Date

November 18, 2022

Conditions
Obesity
Interventions
BIOLOGICAL

maridebart cafraglutide

Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.

DRUG

Placebo

Participants will receive placebo as a single dose in Part A and multiple doses in Part B.

Trial Locations (3)

33014

Clinical Pharmacology of Miami, LLC, Miami

92780

Orange County Research Center, Tustin

92801

Anaheim Clinical Trials, Anaheim

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT04478708 - Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity | Biotech Hunter | Biotech Hunter